Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria
- 13 October 2004
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 60 (10) , 709-715
Abstract
The combination of chloroquine and methylene blue is potentially effective for the treatment of chloroquine-resistant malaria caused by Plasmodium falciparum. The aim of this study was to investigate whether methylene blue influences the pharmacokinetics of chloroquine.Keywords
This publication has 27 references indexed in Scilit:
- IN VITRO METABOLISM OF CHLOROQUINE: IDENTIFICATION OF CYP2C8, CYP3A4, AND CYP2D6 AS THE MAIN ISOFORMS CATALYZING N-DESETHYLCHLOROQUINE FORMATIONDrug Metabolism and Disposition, 2003
- The contribution of clinical pharmacology to antimalarial drug discovery and development2003
- Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparumBiochemical Journal, 2002
- Chloroquine‐Resistant MalariaThe Journal of Infectious Diseases, 2001
- Mechanisms and clinical implications of renal drug excretion*Drug Metabolism Reviews, 2001
- Leakage of enteric (Eudragit® L)-coated dosage forms in simulated gastric juice in the presence of poly(ethylene glycol)Journal of Controlled Release, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996
- Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assayAnti-Cancer Drugs, 1996
- Chloroquine Elimination in Humans: Effect of Low‐Dose CimetidineThe Journal of Clinical Pharmacology, 1987